GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aptabio Therapeutics Inc (XKRX:293780) » Definitions » EV-to-Revenue

Aptabio Therapeutics (XKRX:293780) EV-to-Revenue : 120.34 (As of Jun. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aptabio Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aptabio Therapeutics's enterprise value is ₩113,316.0 Mil. Aptabio Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩941.6 Mil. Therefore, Aptabio Therapeutics's EV-to-Revenue for today is 120.34.

The historical rank and industry rank for Aptabio Therapeutics's EV-to-Revenue or its related term are showing as below:

XKRX:293780' s EV-to-Revenue Range Over the Past 10 Years
Min: 47.7   Med: 2054.71   Max: 8223.32
Current: 120.34

During the past 7 years, the highest EV-to-Revenue of Aptabio Therapeutics was 8223.32. The lowest was 47.70. And the median was 2054.71.

XKRX:293780's EV-to-Revenue is ranked worse than
96.86% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 2.16 vs XKRX:293780: 120.34

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-25), Aptabio Therapeutics's stock price is ₩6640.00. Aptabio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₩40.15. Therefore, Aptabio Therapeutics's PS Ratio for today is 165.40.


Aptabio Therapeutics EV-to-Revenue Historical Data

The historical data trend for Aptabio Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptabio Therapeutics EV-to-Revenue Chart

Aptabio Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 324.41 1,527.30 3,588.97 4,567.12 504.44

Aptabio Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,776.40 3,705.94 3,002.42 504.44 129.10

Competitive Comparison of Aptabio Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aptabio Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptabio Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aptabio Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aptabio Therapeutics's EV-to-Revenue falls into.



Aptabio Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aptabio Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=113315.987/941.613
=120.34

Aptabio Therapeutics's current Enterprise Value is ₩113,316.0 Mil.
Aptabio Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩941.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptabio Therapeutics  (XKRX:293780) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aptabio Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6640.00/40.145
=165.40

Aptabio Therapeutics's share price for today is ₩6640.00.
Aptabio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩40.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptabio Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aptabio Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptabio Therapeutics (XKRX:293780) Business Description

Traded in Other Exchanges
N/A
Address
13, Heungdeok 1-ro, Giheung-gu, Tower 504, Gyeonggi-do, Yongin-Si, KOR, 16954
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.

Aptabio Therapeutics (XKRX:293780) Headlines

No Headlines